Novartis completes shipments of Fluvirin vaccine
7 October 2009 00:00 in Pharmaceutical Company Product News
Novartis has announced that an order made by the US government for 27 million doses of its seasonal influenza vaccine Fluvirin has been shipped.
This marks the earliest that the firm has ever finished such an order, allowing more time for vaccinations ahead of the forthcoming flu season.
At the close of last month, Novartis also began shipments of the first doses of its influenza H1N1 2009 monovalent vaccine to the US, switching production to a new higher yielding seed strain, which allows for deliveries of larger volumes later in the year.
Novartis' H1N1 monovalent vaccine was approved by the Food and Drug Administration on September 15th 2009.
Andrin Oswald, chief executive of Novartis Vaccines and Diagnostics, stated: "We hope that the early delivery of our Fluvirin vaccine will help physicians and public health officials better prepare for the upcoming flu season."
This week, Novartis division Sandoz announced that it has launched its human growth hormone somatropin, which is used to treat hormone deficiencies in children.
Other news stories from 07/10/2009
Related news
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency
